Innovent Biologics Inc

01801

Company Profile

  • Business description

    Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

  • Contact

    168 Dongping Street
    Suzhou Industrial Park
    Jiangsu Province
    Suzhou215123
    CHN

    T: +86 51269566088

    https://www.innoventbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    6,190

Stocks News & Analysis

stocks

Going into earnings, is Netflix stock a buy, a sell, or fairly valued?

Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks

Bapcor is paying for the sins of its past

Shares plunged over 17% after reporting disappointing results.
stocks

Overvalued ASX share as market underestimates downside risks

Growth outlook solid, but upside more than priced in.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,390.1016.400.17%
CAC 408,217.6811.610.14%
DAX 4024,229.4629.34-0.12%
Dow JONES (US)46,706.58515.971.12%
FTSE 1009,423.1419.570.21%
HKSE26,027.55168.720.65%
NASDAQ22,990.54310.571.37%
Nikkei 22549,316.06130.560.27%
NZX 50 Index13,377.8532.890.25%
S&P 5006,735.1371.121.07%
S&P/ASX 2009,094.7018.800.21%
SSE Composite Index3,916.3352.441.36%

Market Movers